RxDoctor Payments Data

Kenneth Eckmann, MD

Neurology · Silver Spring, MDNPI 1982676201

Payments from drug & device makers

$19,105in general payments, 2019–2025

Across 1,005 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Pfizer$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$1K
  • Lilly USA, LLC$1K
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$720%
  • Food & beverage$18,87199%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)134$2,864
Novartis168$2,412
Pfizer87$1,464
Teva Pharmaceuticals USA, Inc.56$1,265
Biogen63$1,209
Lilly USA, LLC63$1,160
UCB, Inc.26$636
Lundbeck LLC22$497
Amgen(2 entities)22$488
Amneal Pharmaceuticals LLC15$442
Acadia Pharmaceuticals Inc20$401
Sunovion Pharmaceuticals Inc.22$375
Genentech USA, Inc.16$358
Biohaven Pharmaceutical Holding Company Ltd.35$327
EMD Serono, Inc.16$314
Eisai Inc.12$285
Sanofi13$261
Banner Life Sciences, LLC13$261
AstraZeneca(2 entities)9$223
MDD US Operations, LLC6$222
Kyowa Kirin, Inc.11$216
Neurocrine Biosciences, Inc.10$210
Bristol Myers Squibb13$209
Neurelis, Inc.13$199
Argenx US, Inc.10$180
Axsome Therapeutics, Inc.6$169
Upsher-smith Laboratories LLC8$165
Biohaven Pharmaceuticals, Inc.18$164
Jazz Pharmaceuticals Inc.8$153
CSL Behring7$144
Mallinckrodt Hospital Products Inc.5$132
GE HealthCare4$128
Insightec,inc2$128
Johnson & Johnson(2 entities)4$119
TG Therapeutics, Inc.4$116
Impel Pharmaceuticals Inc.6$98
Acorda Therapeutics, Inc5$89
Adamas Pharmaceuticals, Inc.4$76
Avion Pharmaceuticals4$69
Impel Pharmaceuticals LLC3$68
Supernus Pharmaceuticals, Inc.3$60
Arbor Pharmaceuticals, Inc.3$48
Vanda Pharmaceuticals Inc.2$48
E.r. Squibb & Sons, L.L.C.3$45
Averitas Pharma Inc.2$44
SK Life Science, Inc.2$42
Abbott2$39
Catalyst Pharmaceuticals, Inc.2$39
Avanir Pharmaceuticals, Inc.2$34
Alnylam Pharmaceuticals Inc.1$33
Mallinckrodt Enterprises LLC1$33
Nevro Corp.1$28
Corium, LLC1$27
Vertical Pharmaceuticals, LLC2$27
Xeris Pharmaceuticals, Inc.1$23
Grifols USA, LLC1$23
Merz Pharmaceuticals, LLC1$22
Otsuka America Pharmaceutical, Inc.1$22
Assertio Therapeutics, Inc.1$19
Cycle Pharmaceuticals Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,105 in reported general payments places this provider in the 75th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$267,327
Medicare patients
719
Services billed
2,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b12$115,158
RexultiBrexpiprazole18$24,077
Memantine Hcl155$4,105
Rivastigmine21$3,152
Donepezil Hcl184$2,131
Pregabalin51$1,852
RivastigmineRivastigmine Tartrate11$1,750
Carbidopa-LevodopaCarbidopa/Levodopa78$1,687
Primidone39$1,507
Amitriptyline Hcl41$1,155
Levetiracetam33$1,081
Lidocaine15$822
Carbidopa-Levodopa ErCarbidopa/Levodopa18$747
Pyridostigmine Bromide13$624
Gabapentin60$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$22$24,07718 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$442$62413 claims
Upsher-smith Laboratories LLCTopiramate$165$34632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 442 neurology providers in Maryland.

Other neurology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →